Pooled CRISPR knockout screening in Drosophila cells enables high-resolution, genome-wide functional genomic comparisons in cell-lines across vast evolutionary distance.
Functional genomic screening reveals new synthetic lethality with and modes of resistance to epidermal growth factor receptor (EGFR) targeted therapy in EGFR-mutant human lung cancer.
CRISPR/Cas9 screens reveal a role for the ubiquitin ligase substrate adaptor DCAF15 in the immune surveillance of cancer cells by natural killer cells.
The protein p53 negatively impacts the ability of a CRISPR screen to discriminate between essential and non-essential genes, hence, p53 status should be considered in these screens.
Integrated modeling of sgRNA positioning, chromatin accessibility, and sequence features enables accurate prediction of effective target sites for CRISPR-mediated transcriptional modulation and design of highly active libraries for genome-scale genetic screens.
An multi-species approach can be used to identify small molecules with properties that might prove useful for the treatment of some neuromuscular diseases.
The reclassification of gene editing as "GM" will impact on European plant sciences, making it more difficult to validate new traits in field trials and drive forward innovation.
An EASAC working group on genome editing recommends that regulators should focus on specific applications of these new techniques rather than attempting to regulate genome editing itself as a new technology.
